- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Potential retinal disease treatments to be presented at ARVO
Preclinical results for two new compounds (Sirion) that may be used for the treatment of retinal diseases will be presented during the 2008 annual meeting of the Association for Research in Vision and Ophthalmology.
Tampa, FL-Preclinical results for two new compounds (Sirion) that may be used for the treatment of retinal diseases will be presented during the 2008 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), April 27 to May 1, Fort Lauderdale, FL.
The new class oxidative stress modulator will be presented at, "Development of topically applied modulators of ocular oxidative stress" on Wednesday, April 30, 3:15 to 3:30 p.m., Grand Floridian H.
The small molecule non-retinoid modulator will be discussed in a presentation, "Development of non-retinoid therapeutics for the treatment of lipofuscin based retinopathies," on Wednesday, April 30, 3:45 to 4 p.m., Grand Floridian B.
